Compare TransMedics Group Inc (TMDX) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs US Bancorp — how do they compare? TransMedics Group Inc trades at $85.89 (market cap $3.06B), while US Bancorp trades at $62 (market cap $97.36B). The key difference: US Bancorp is far larger — about 31.8× TransMedics Group Inc's market cap, and US Bancorp pays a 3.33% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | USB | |
|---|---|---|
Market Cap | $3.06B | $97.36B |
Sector | Technology | Financials |
52-Week High | $150.42 | $65.42 |
52-Week Low | $61.99 | $45.28 |
Enterprise Value | $3.46B | — |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
U.S. Bancorp (USB) trades at $62.49, down 1.39% today, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with a P/E of 12.47 and net income margin of 27.61%, supported by three consecutive quarterly EPS beats. Recent news highlights innovation in digital payments and business banking expansion. Cash flow trends indicate volatility, with 2025 net cash flow negative at -$9.61 billion.
The outlook is mixed: analyst consensus targets $70.27 (12.4% upside) with 50% buy ratings, but technicals suggest near-term pressure. Key risks include debt levels and macroeconomic sensitivity. Earnings growth and dividend stability ($0.52 quarterly) provide support, though investor sentiment is cautious amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
